MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 05-14-2026
AstraZeneca PLC Total Assets 2011-2026 | AZN
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets AstraZeneca PLC
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 114 B | 104 B | 101 B | 96.5 B | 105 B | 66.7 B | 61.4 B | 60.7 B | 63.4 B | 62.5 B | 60.1 B | 58.6 B | 55.9 B | 53.5 B | 52.8 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 114 B | 52.8 B | 74.4 B |
Quarterly Total Assets AstraZeneca PLC
| 2025-Q4 | 2025-Q2 | 2024-Q4 | 2024-Q2 | 2023-Q4 | 2023-Q2 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 114 B | 112 B | 104 B | 104 B | 101 B | 96.5 B | - | - | - | - | 105 B | - | 73.6 B | - | 66.7 B | - | 59.9 B | - | 61.4 B | - | 61.9 B | - | 60.7 B | - | 61.3 B | - | 63.4 B | - | 65.1 B | - | 62.5 B | - | - | - | 60.1 B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 114 B | 59.9 B | 79.7 B |
Total Assets of other stocks in the Biotechnology industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
FSD Pharma
HUGE
|
11.2 M | - | 5743.5 % | $ 69.7 M |  Canada |
 |
MorphoSys AG
MOR
|
2.03 B | - | 2.43 % | $ 254 M |  Germany |
 |
Happiness Biotech Group Limited
HAPP
|
35.6 M | - | 1.35 % | $ 17.8 M |  China |
 |
Amphastar Pharmaceuticals
AMPH
|
1.63 B | $ 16.88 | -2.43 % | $ 789 M |  USA |
 |
AgeX Therapeutics
AGE
|
6.95 M | - | -10.17 % | $ 12.2 K | USA |
 |
Compugen Ltd.
CGEN
|
157 M | $ 2.79 | -8.09 % | $ 261 M |  Israel |
 |
Coherus BioSciences
CHRS
|
258 M | $ 1.6 | -2.15 % | $ 187 M | USA |
 |
I-Mab
IMAB
|
6.33 B | - | - | $ 866 M | China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
18.1 B | - | - | $ 40.3 B | USA |
 |
Biophytis SA
BPTS
|
12 M | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
151 M | - | 2.54 % | $ 160 B | France |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
15.2 M | - | -1.52 % | $ 24.7 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
271 M | $ 7.56 | -3.45 % | $ 207 M | Israel |
 |
Athira Pharma
ATHA
|
92.2 M | - | - | $ 269 M | USA |
 |
BiondVax Pharmaceuticals Ltd.
BVXV
|
99.6 M | - | 0.74 % | $ 768 M | Israel |
 |
Galera Therapeutics
GRTX
|
7.2 M | - | -32.59 % | $ 7.61 M | USA |
 |
Esperion Therapeutics
ESPR
|
466 M | $ 3.13 | 0.32 % | $ 651 M | USA |
 |
Exelixis
EXEL
|
2.84 B | $ 50.41 | -1.36 % | $ 13.7 B | USA |
 |
Fortress Biotech
FBIO
|
186 M | $ 2.43 | 5.65 % | $ 67.8 M | USA |
 |
Midatech Pharma plc
MTP
|
18.2 M | - | -18.52 % | $ 27.3 M |  Britain |
|
Forte Biosciences
FBRX
|
82.8 M | $ 23.1 | -3.57 % | $ 299 M | USA |
 |
Fennec Pharmaceuticals
FENC
|
70.6 M | $ 9.76 | 5.63 % | $ 279 M | USA |
 |
AbCellera Biologics
ABCL
|
1.36 B | $ 4.09 | -7.05 % | $ 1.22 B | Canada |
 |
Autolus Therapeutics plc
AUTL
|
589 M | $ 1.59 | - | $ 423 M | Britain |
 |
Институт стволовых клеток человека
ISKJ
|
1.51 B | - | - | - |  Russia |
 |
BioNTech SE
BNTX
|
22 B | $ 89.16 | -3.08 % | $ 21.5 B | Germany |
 |
Checkmate Pharmaceuticals
CMPI
|
78.8 M | - | - | $ 231 M | USA |
 |
Galectin Therapeutics
GALT
|
19.5 M | $ 2.22 | -5.74 % | $ 142 M | USA |
 |
Gilead Sciences
GILD
|
59 B | $ 130.07 | -1.51 % | $ 162 B | USA |
 |
Genmab A/S
GMAB
|
45.8 B | $ 26.8 | -0.37 % | $ 1.73 B |  Danmark |
 |
Advaxis
ADXS
|
16.6 M | - | -9.65 % | $ 45.9 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
9.51 M | $ 3.41 | -2.25 % | $ 5.61 M | Israel |
 |
Aeterna Zentaris
AEZS
|
21.4 M | - | 5.93 % | $ 314 M | Canada |
 |
Aeglea BioTherapeutics
AGLE
|
778 M | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
1.16 B | - | - | $ 867 M | Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
66.7 M | - | - | $ 26.5 M | USA |
 |
Grifols, S.A.
GRFS
|
21.4 B | $ 7.74 | -0.64 % | $ 5.26 B |  Spain |
 |
AIkido Pharma
AIKI
|
113 M | - | 1.93 % | $ 17.4 M | USA |
|
Enlivex Therapeutics Ltd.
ENLV
|
2.33 B | $ 0.72 | -1.05 % | $ 32.9 M | Israel |
 |
Akero Therapeutics
AKRO
|
826 M | - | - | $ 3.67 B | USA |
 |
Eton Pharmaceuticals
ETON
|
92.1 M | $ 29.69 | -0.92 % | $ 799 M | USA |
 |
Aptose Biosciences
APTO
|
10 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
66.7 M | - | -39.0 % | $ 4.57 M | USA |
 |
Akouos
AKUS
|
279 M | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
302 M | - | -0.23 % | $ 916 M | USA |
 |
AlloVir
ALVR
|
122 M | - | 4.14 % | $ 49.1 M | USA |
 |
Allakos
ALLK
|
244 M | - | - | $ 28.6 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
433 M | $ 21.51 | -0.3 % | $ 2.74 B | USA |
 |
Allena Pharmaceuticals
ALNA
|
34.8 M | - | 3.16 % | $ 1.9 M | USA |